Alerts will be sent to your verified email
Verify Email
BETA
Insufficient data
Positive for this company
Neutral for this company
Negative for this company
Insufficient data to analyse
Beta Drugs, a part of Adley Group, specializes in manufacturing oncology products like anti-cancer tablets, capsules, injections, and lyophilized injections. With a portfolio of over 50 products, it caters to the treatment of various cancer diseases.
Beta Drugs major competitors are Bliss GVS Pharma, Syncom Formulations, Jagsonpal Pharma, Novartis, Indoco Remedies, Panacea Biotec, Lincoln Pharma.
Market Cap of Beta Drugs is ₹1,899 Crs.
While the median market cap of its peers are ₹1,670 Crs.
Beta Drugs seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annual Report | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | ||
| Earnings Release | ||||||||||||||||||
| Investor Presentation | Mar Sep | |||||||||||||||||
| Conference Call | Mar Sep | |||||||||||||||||
|
Conference Call SummaryCon Call Summary
Powered by Gemini
|
